Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Discussion: Further, a review of K65R suggested that the mutation is uncommon, and individuals infected with subtype C HIV may be at a greater risk of acquiring the mutation.
Discussion: Interestingly, we would expect the subsequent appearance of TDF/FTC-associated mutations, but we only observed one case of M184V in 2006 and zero cases of K65R, which are major NRTI mutations selected for by FTC/3TC and TDF, respectively.
Discussion: This may be due to the lower selectivity of FTC for M184V and the inhibitive action of M184V and K65R on viral fitness.
Discussion: Unfortunately, we were unable to fully characterize the HIV subtypes of our study sample, so it is unclear if the absence of K65R in our
HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Result: M184V/I (236/372, 63.44%), K65KR/R (78/372, 20.97%), D67DN/N (77/372, 20.70%), and K70E/R/KR (72/372, 19.35%) were most common NRTI-related mutations.
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Method: The proportion of patients with M184 V/I, K103 N/S, and K65R mutations, as well as the presence of thymidine analogue mutations (TAMs) were also reported.
Result: M184 V/I, K65R and TAMs were uncommon, as was multidrug resistance.
Table: K65R
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Introduction: For example, studies have shown, subtype C may acquire the tenofovir-related mutation K65R more rapidly when compared to subtype B, while mutations associated with resistance to rilpivirine are rare in infected patients with HIV-1 subtypes CRF01-A/E failing a first-line NNRTI-containing regimen.
Table: K65R
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
Method: Presence or absence of the K65R mutation was also included as a predictor, and analyses were also conducted including the respective accessory mutations for Q151M and T69i.
Result: Only 3% of patients showed no other mutation, and the most common associated major reverse transcriptase mutations were M184V (47%), K103N (35%) and K65R (29%).
Result: There was no strong evidence that linked TAMs were associated with the probability of viral suppression, although negative effects cannot be ruled out, and there were no cases with a K65R mutation included in this analysis.
Table: K65R
A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
Abstract: The 1 subject with virologic failure had multidrug-resistant HIV-2 (reverse transcriptase mutation: K65R; integrase mutations: G140S and Q148R) detected at week 48.
Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
HIV mutation literature information.
PMID: 
2019
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT